A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Tim Hortons sponsor community outreach programs include Free Skating, Free Swimming, Earn-a-Bike, Remembrance Day, Food Drives, and the Smile Cookie programs (not to be confused with the similar Smiley Cookie sold at regional chain Eat'n Park), as well as community clean-up projects. In a collaboration with Canadian DJ Deadmau5, the Smile Cookie program raised $7.8 million. The store promotes itself through the Tim Horton Children's Foundation. Founded by Ron Joyce, the foundation sponsors thousands of underprivileged children from Canada and the United States to go to one of six high-class summer camps in Parry Sound, Ontario; Tatamagouche, Nova Scotia; Kananaskis Country, Alberta; Quyon, Quebec; Campbellsville, Kentucky; St. George, Ontario; and most recently Whiteshell Provincial Park, Manitoba. The foundation's highest-profile fundraiser is Camp Day, held annually on the Wednesday of the first full week in June. All proceeds from coffee sales at most Tim Hortons locations, as well as proceeds from related activities held that day, are donated to the foundation. Small stores in Esso Service Stations do not donate coffee proceeds on Camp Day. Joyce's work with the Tim Horton Children's Foundation earned him the Gary Wright Humanitarian Award in 1991, presented periodically in recognition of contributions to the betterment of community life throughout Canada. In recognition primarily for his work with the Foundation, he received an appointment to the Order of Canada, with the official presentation taking place on October 21, 1992, in Ottawa.
==== Punishing states with cuts to Homeland Security funding ==== The U.S. Department of Homeland Security and the Federal Emergency Management Agency (FEMA) reduced more than $233 million from Connecticut, Delaware, Massachusetts, Minnesota, New York, Rhode Island, Vermont, and Washington state because they had failed to cooperate with Trump immigration policy. In addition, funding was cut to the District of Columbia. In December, a federal judge ruled that the Trump administration could not do this, stating in her decision, "To hold hostage funding for programs like these based solely on what appear to be defendants' political whims is unconscionable and, at least here, unlawful."
On the culmination of the Consumer Healthcare string of deals, GSK split into two separate companies, via a demerger and subsequent listing of the joint venture. This created two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare. On 22 February 2022, GSK announced that the spin-off consumer healthcare company would be called Haleon. In January 2022, the company announced that they had received three unsolicited offers from Unilever to acquire the Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 billion in cash, plus £8.3 billion in Unilever shares). However GSK declined all outside offers/attempts to acquire its consumer healthcare business and moved forward with its plan to complete the demerger from the main biopharmaceutical business.
=== Bulk measurement === Generally speaking bulk measurement instruments thermally vaporize the particles prior to ionization, and there are several different ways that the vaporization and ionization is performed. The main instrument that is used for bulk measurements is Aerodyne aerosol mass spectrometer (AMS).
=== Pharmacodynamics === Similarly to MDA, SDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT2 receptor agonist. However, SDA was 16-fold more potent as a serotonin releaser, 16-fold more potent as a dopamine releaser, and 2-fold more potent as a norepinephrine releaser than MDA in HEK293 cells in vitro. In addition, it was 2- to 3-fold more potent as an agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors than MDA. SDA had largely similar activational efficacies at the serotonin 5-HT2 receptors as MDA. Due to its greater potency as a monoamine releasing agent, SDA may be active at lower doses or concentrations than MDA. SDA produced hyperlocomotion and hyperthermia in rodents and to a greater extent than SDMA or MDMA. However, SDA did not produce significant rewarding effects in the conditioned place preference (CPP) paradigm unlike MDMA but similarly to SDMA. Hence, SDA might have reduced misuse potential compared to other related drugs like MDMA. Similarly to findings with MDA, SDA produced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may produce hallucinogenic effects in humans. Unlike SDMA and MDMA, SDA produced thigmotaxis in the open field test, an anxiety-like effect. SDA may be cardiotoxic due to serotonin 5-HT2B receptor agonism.
Sources: en.wikipedia.org
Jens Juul Holst (born 31 August 1945) is a Danish physician and physiologist. He is known for discovering and describing the hormone glucagon-like peptide-1 (GLP-1), a hormone in the gut that plays an important role in the onset and development of Type 2 diabetes. In collaboration with researcher and author Arne Astrup, he discovered that GLP-1 acts as a satiety hormone in humans. In 2020, he was awarded the Warren Alpert Foundation Prize along Daniel J. Drucker and Joel F. Habener. In 2021, he was awarded the Canada Gairdner International Award along Daniel J. Drucker, Joel F. Habener, and Mary-Claire King. He was also awarded the Banting Medal by the American Diabetes Association (ADA). In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, and Svetlana Mojsov. In 2024, he received the Tang Prize in the category of "Biopharmaceutical Science", and the BBVA Foundation Frontiers of Knowledge Award in the category "Biology and Biomedicine". In 2025, he received the Breakthrough Prize in Life Sciences alongside Daniel Drucker, Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen).
A construct in chemistry is molecular symmetry, as embodied in Group theory. Inorganic compounds display a particularly diverse symmetries, so it is logical that Group Theory is intimately associated with inorganic chemistry. Group theory provides the language to describe the shapes of molecules according to their point group symmetry. Group theory also enables factoring and simplification of theoretical calculations. Spectroscopic features are analyzed and described with respect to the symmetry properties of the, inter alia, vibrational or electronic states. Knowledge of the symmetry properties of the ground and excited states allows one to predict the numbers and intensities of absorptions in vibrational and electronic spectra. A classic application of group theory is the prediction of the number of C–O vibrations in substituted metal carbonyl complexes. The most common applications of symmetry to spectroscopy involve vibrational and electronic spectra. Group theory highlights commonalities and differences in the bonding of otherwise disparate species. For example, the metal-based orbitals transform identically for WF6 and W(CO)6, but the energies and populations of these orbitals differ significantly. A similar relationship exists between CO2 and molecular beryllium difluoride.
==== Restoration of Ferdinand VII ==== In March 1814, following the collapse of the First French Empire, Ferdinand VII was restored to the Spanish throne. This signified an important change, since most of the political and legal changes made on both sides of the Atlantic—the myriad of juntas, the Cortes in Spain and several of the congresses in the Americas, and many of the constitutions and new legal codes—had been made in his name. Before entering Spanish territory, Ferdinand made loose promises to the Cortes that he would uphold the Spanish Constitution. But once in Spain he realized that he had significant support from conservatives in the general population and the hierarchy of the Spanish Catholic Church; so, on 4 May, he repudiated the Constitution and ordered the arrest of liberal leaders on 10 May. Ferdinand justified his actions by stating that the Constitution and other changes had been made by a Cortes assembled in his absence and without his consent. He restored the former legal codes and political institutions and promised to convene a new Cortes under its traditional form (with separate chambers for the clergy and the nobility), a promise never fulfilled. News of the events arrived through Spanish America during the next three weeks to nine months, depending on time it took goods and people to travel from Spain.
None of modern Pakistan was under British rule until 1839 when Karachi, a small fishing village governed by Talpurs of Sindh with a mud fort guarding the harbour, was taken, and used as an enclave with a port and military base for the First Afghan War that ensued. The remainder of Sindh was acquired in 1843, and subsequently, through a series of wars and treaties, the East India Company, and later, after the Sepoy Mutiny (1857–1858), direct rule by Queen Victoria of the British Empire, acquired most of the region. Key conflicts included those against the Baloch Talpur dynasty, resolved by the Battle of Miani (1843) in Sindh, the Anglo-Sikh Wars (1845–1849), and the Anglo-Afghan Wars (1839–1919). By 1893, modern Pakistan was part of the British Indian Empire, and remained so until independence in 1947. Under British rule, modern Pakistan was primarily divided into the Sind Division, Punjab Province, and the Baluchistan Agency. The region also included various princely states, with the largest being Bahawalpur. An important uprising against the British in the region was the Indian Rebellion of 1857, known at the time as the Sepoy Mutiny. Divergence in the relationship between Hinduism and Islam resulted in significant tension in British India, leading to religious violence. The language controversy further exacerbated tensions between Hindus and Muslims. A Muslim intellectual movement, led by Sir Syed Ahmed Khan to counter the Hindu renaissance, advocated for the two-nation theory and led to the establishment of the All-India Muslim League in 1906.
Calcium gluconate is the calcium salt of gluconic acid and is used as a mineral supplement and medication. As a medication it is used by injection into a vein to treat low blood calcium, high blood potassium, and magnesium toxicity. Supplementation is generally only required when there is not enough calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets. It can also be taken by mouth but is not recommended for injection into a muscle. Side effects when injected include slow heart rate, pain at the site of injection, and low blood pressure. When taken by mouth side effects may include constipation and nausea. Blood calcium levels should be measured when used and extra care should be taken in those with a history of kidney stones. At normal doses, use is regarded as safe in pregnancy and breastfeeding. Calcium gluconate is made by mixing gluconic acid with calcium carbonate or calcium hydroxide. Calcium gluconate came into medical use in the 1920s. It is on the World Health Organization's List of Essential Medicines. Calcium gluconate is available as a generic medication. It is closely related to calcium borogluconate, which is commonly used in veterinary medicine owing to its higher solubility. It is used for intravenous administration of calcium, notably in ruminants.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.